BVF PARTNERS L P/IL - 17 Feb 2026 Form 3 Insider Report for IMMUNIC, INC. (IMUX)

Role
Director, Other*
Signature
BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Issuer symbol
IMUX
Transactions as of
17 Feb 2026
Net transactions value
$0
Form type
3
Filing time
27 Feb 2026, 17:03:09 UTC
Previous filing
30 Jan 2026
SEC
View on sec.gov

Reporting Owners (10)

Name Relationship Address Signature Signature date CIK
BVF PARTNERS L P/IL Director, Other* 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 27 Feb 2026 0001055947
BIOTECHNOLOGY VALUE FUND L P Director, Other* 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer 27 Feb 2026 0000918923
BVF I GP LLC Director, Other* 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 27 Feb 2026 0001803805
BIOTECHNOLOGY VALUE FUND II LP Director, Other* 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer 27 Feb 2026 0001102444
BVF II GP LLC Director, Other* 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 27 Feb 2026 0001803806
Biotechnology Value Trading Fund OS LP Director, Other* P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 27 Feb 2026 0001660683
BVF Partners OS Ltd. Director, Other* P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN, CAYMAN ISLANDS Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President 27 Feb 2026 0001660684
BVF GP HOLDINGS LLC Director, Other* 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer 27 Feb 2026 0001803809
BVF INC/IL Director, Other* 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO BVF Inc., By: /s/ Mark N. Lampert, President 27 Feb 2026 0001056807
LAMPERT MARK N Director, Other* 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO /s/ Mark N. Lampert 27 Feb 2026 0001233840

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IMUX Common Stock, $0.0001 par value 4,135,956 17 Feb 2026 Direct F1, F2
holding IMUX Common Stock, $0.0001 par value 3,027,105 17 Feb 2026 Direct F1, F3
holding IMUX Common Stock, $0.0001 par value 427,629 17 Feb 2026 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMUX Pre-Funded Warrants to Purchase Common Stock 17 Feb 2026 Common Stock, $0.0001 par value 4,496,000 Direct F1, F2, F5
holding IMUX Pre-Funded Warrants to Purchase Common Stock 17 Feb 2026 Common Stock, $0.0001 par value 3,514,428 Direct F1, F3, F5
holding IMUX Pre-Funded Warrants to Purchase Common Stock 17 Feb 2026 Common Stock, $0.0001 par value 444,452 Direct F1, F4, F5
holding IMUX Pre-Funded Warrants to Purchase Common Stock 17 Feb 2026 Common Stock, $0.0001 par value 6,817,521 Direct F1, F2, F6
holding IMUX Pre-Funded Warrants to Purchase Common Stock 17 Feb 2026 Common Stock, $0.0001 par value 5,278,894 Direct F1, F3, F6
holding IMUX Pre-Funded Warrants to Purchase Common Stock 17 Feb 2026 Common Stock, $0.0001 par value 912,813 Direct F1, F4, F6
holding IMUX Pre-Funded Warrants to Purchase Common Stock 17 Feb 2026 Common Stock, $0.0001 par value 28,797,932 Direct F1, F2, F7
holding IMUX Pre-Funded Warrants to Purchase Common Stock 17 Feb 2026 Common Stock, $0.0001 par value 20,525,707 Direct F1, F3, F7
holding IMUX Pre-Funded Warrants to Purchase Common Stock 17 Feb 2026 Common Stock, $0.0001 par value 3,202,262 Direct F1, F4, F7
holding IMUX Warrants to Purchase Common Stock 17 Feb 2026 Common Stock, $0.0001 par value 28,797,932 Direct F1, F2, F8, F9
holding IMUX Warrants to Purchase Common Stock 17 Feb 2026 Common Stock, $0.0001 par value 20,525,707 Direct F1, F3, F8, F9
holding IMUX Warrants to Purchase Common Stock 17 Feb 2026 Common Stock, $0.0001 par value 3,202,262 Direct F1, F4, F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 3 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
F2 Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general parter of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
F3 Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
F4 Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
F5 The Reporting Persons hold certain Pre-Funded Warrants (the "2024 Pre-Funded Warrants") exercisable for an aggregate of 8,580,151 shares of Common Stock. The 2024 Pre-Funded Warrants do not expire and have an exercise price of $0.0001 per share. The 2024 Pre-Funded Warrants are exercisable immediately, except that the 2024 Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.9% of the shares of Common Stock outstanding.
F6 The Reporting Persons hold certain Pre-Funded Warrants (the "2025 Pre-Funded Warrants") exercisable for an aggregate of 13,335,000 shares of Common Stock. The 2025 Pre-Funded Warrants do not expire and have an exercise price of $0.0001 per share. The 2025 Pre-Funded Warrants are exercisable immediately, except that the 2025 Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares of Common Stock outstanding.
F7 The Reporting Persons hold certain Pre-Funded Warrants (the "2026 Pre-Funded Warrants") exercisable for an aggregate of 53,257,500 shares of Common Stock. The 2026 Pre-Funded Warrants do not expire and have an exercise price of $0.0001 per share. The 2026 Pre-Funded Warrants are exercisable immediately, except that the 2026 Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares of Common Stock outstanding.
F8 The Reporting Persons hold certain Warrants (the "Common Warrants") exercisable for an aggregate of 53,257,500 shares of Common Stock. The Common Warrants are exercisable at a price $0.873220 per share of Common Stock following the completion of the Issuer's reverse stock split until the earlier of (i) 30 trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 ENSURE trials (for the avoidance of doubt, the later date of the initial public announcement of topline data from ENSURE-1 or ENSURE-2, if announced separately) (the "Topline Data Announcement"), (ii) immediately upon the exercise of the 2026 Pre-Funded Warrants if such exercise of 2026 Pre-Funded Warrants is prior to the Topline Data Announcement, provided that if the 2026 Pre-Funded Warrant is not exercised in full, the Common Warrant expires proportionally only to the extent the 2026 Pre-Funded Warrant is exercised, and (iii) February 17, 2031.
F9 The Common Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares of Common Stock outstanding.

Remarks:

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a Principal of Partners, R. Thorvald Nagel, serving on the Board of Directors of the Issuer, and his agreement to transfer to Partners the economic benefit, if any, received upon the sale of any securities of the Issuer he receives in his capacity as a director of the Issuer.